Trial Profile
Effect of Pharmacological Heart Rate Reduction on Visco-elastic Properties of the Arterial Wall (BRADYVASC)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 08 Jun 2020
Price :
$35
*
At a glance
- Drugs Ivabradine (Primary)
- Indications Angina pectoris; Chronic heart failure; Coronary artery disease; Low cardiac output; Tachycardia
- Focus Therapeutic Use
- Acronyms BRADYVASC
- 07 Jun 2020 This trial is completed, according to European Clinical Trials Database record.
- 25 May 2016 Status changed from not yet recruiting to recruiting.
- 27 Oct 2015 New trial record